Beam Therapeutics Inc
Q2 2026 Earnings
Market Reaction
Did BEAM Beat Earnings? Q2 2026 Results
Beam Therapeutics delivered a sharply disappointing second quarter, missing on both top and bottom lines as the gene editing company's financial results diverged significantly from its clinical momentum. Revenue collapsed 94.2% year-over-year to just $490,000, falling far short of the $17.20 million consensus estimate, a 97.15% miss driven by a steep decline in license and collaboration revenue compared to the $8.47 million recorded in Q2 2025. On the bottom line, Beam posted a loss of $1.18 per share, missing the $1.13 consensus estimate by 4.80%, as the net loss widened to $122.68 million from $102.14 million in the prior-year period. The wider loss reflected reduced revenue and lower other income, only partially offset by modestly lower R&D expenses of $95.10 million. Despite the financial shortfall, the pipeline continued to advance, with the first patient dosed in the global pivotal BEAM-302 trial for AATD and a potential BLA submission for risto-cel in sickle cell disease expected as early as year-end 2026. Analysts tracking the stock have maintained broadly constructive views on the pipeline's longer-term value, and the company's $1.15 billion cash position, supplemented by a $200 million credit facility, is expected to fund operations into mid-2029.
- Significant decline in license and collaboration revenue from $8.5 million to $0.5 million year-over-year
- Lower R&D expenses partially offset by higher G&A expenses
- Reduced other income of $3.9 million versus $18.0 million in prior-year quarter
“The second quarter marked another period of rapid progress and disciplined execution on the clinical, regulatory and operational milestones we set for Beam. Importantly, this progress enabled dosing of the first patient in the global pivotal cohort evaluating BEAM-302, the most advanced genetic medicine in development for AATD, which has the potential to fundamentally change the treatment paradigm for patients. In addition, we completed dosing for all adult and adolescent SCD patients in the BEACON trial of risto-cel and received FDA clearance of the IND for BEAM-304 in PKU, paving the way to the clinic for this next potentially high-value franchise.”
Beam Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
Beam expects its cash, cash equivalents and marketable securities of $1.2 billion as of June 30, 2026, together with an additional $200 million expected to be drawn from its credit facility with Sixth Street, to fund operations into mid-2029. This runway is expected to support the anticipated launch of risto-cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and clinical proof of concept for BEAM-304 in PKU. Near-term milestones include updated BEAM-302 data at the ERS Congress in September 2026, initial BEAM-301 clinical data in 2026, updated BEACON trial data by year-end 2026, and a potential BLA submission for risto-cel as early as year-end 2026.
BEAM YoY Financials
Figures from SEC filings and company reports. Not investment advice.